SLC6A3 and Parkinson disease: Although it has been suggested that prasinezumab may be effective against the diffuse malignant form of PD—which refers to an aggressive and rapidly progressing subtype of the disease characterized by widespread neurodegeneration (Pagano et al., 2024)—there were no significant changes in clinical indicators, dopamine transporter SPECT, MRI, neurofilament light chain, or other PD biomarkers following administration of cimpanema (Hutchison et al., 2024).